Journal of Liver Cancer最新文献

{"title":"Clinical characteristics and prognosis of Korean patients with hepatocellular carcinoma with respect to etiology.","authors":"Wonjoon Jang,&nbsp;Hye Won Lee,&nbsp;Jae Seung Lee,&nbsp;Beom Kyung Kim,&nbsp;Seung Up Kim,&nbsp;Jun Yong Park,&nbsp;Sang Hoon Ahn,&nbsp;Do Young Kim","doi":"10.17998/jlc.2022.09.18","DOIUrl":"https://doi.org/10.17998/jlc.2022.09.18","url":null,"abstract":"<p><strong>Background/aim: </strong>The profile of patients with hepatocellular carcinoma (HCC) has changed globally; the role of etiology in predicting prognosis of HCC patients remains unclear. We aimed to analyze the characteristics and prognosis of Korean patients with HCC according to disease etiology.</p><p><strong>Methods: </strong>This retrospective observational study included patients diagnosed with HCC between 2010 and 2014 in a single center in Korea. Patients with HCC aged <19 years old, had coinfection with other viral hepatitis, had missing follow-up data, were Barcelona Clinic Liver Cancer stage D, or died before 1 month were excluded.</p><p><strong>Results: </strong>A total of 1,595 patients with HCC were analyzed; they were classified into the hepatitis B virus (HBV) group (1,183 [74.2%]), hepatitis C virus (HCV) group (146 [9.2%]), and non-B non-C (NBNC) group (266 [16.7%]). The median overall survival of all patients was 74 months. The survival rates at 1, 3, and 5 years were 78.8%, 62.0% and 54.9% in the HBV group; 86.0%, 64.0%, and 48.6% in the HCV group; and 78.4%, 56.5%, and 45.9% in the NBNC group, respectively. NBNC-HCC has a poorer prognosis than other causes of HCC. Survival was significantly longer in the HBV group with early-stage HCC than in the NBNC group. Furthermore, survival was shorter in patients with early-stage HCC and diabetes mellitus (DM) than in those without DM.</p><p><strong>Conclusions: </strong>The etiology of HCC affected clinical characteristics and prognosis to some extent. NBNC-HCC patients showed shorter overall survival than viral-related HCC patients. Additionally, the presence of DM is an additional important prognostic factor in patients with early-stage HCC.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"158-166"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/ea/jlc-2022-09-18.PMC10035743.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9727484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibrolamellar hepatocellular carcinoma that was successfully treated with surgical resection: a case report.","authors":"Seong Kyun Na","doi":"10.17998/jlc.2022.06.10","DOIUrl":"https://doi.org/10.17998/jlc.2022.06.10","url":null,"abstract":"<p><p>Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare malignant hepatic cancer with characteristics that differ from those of typical hepatocellular carcinoma (HCC). Unlike conventional HCC, FLHCC is common in young patients without any underlying liver disease and is known to be associated with a unique gene mutation. This cancer type is rare in Asia, with only a few cases being reported in Korea. We report a case of FLHCC in a young woman that successfully underwent surgical resection. The efficacy of alternative treatments, such as transarterial chemoembolization or systemic chemotherapies, has not yet been established. To conclude, early diagnosis and appropriate surgical resection are important for the treatment of FLHCC.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"178-182"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bc/82/jlc-2022-06-10.PMC10035731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9739879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary approach for hepatocellular carcinoma arising from cirrhotic liver with Budd-Chiari syndrome: a case report.","authors":"Sangmi Kim,&nbsp;Ji Hoon Kim,&nbsp;Ji Won Han,&nbsp;Jeong Won Jang,&nbsp;Jong Young Choi,&nbsp;Seung Kew Yoon,&nbsp;Pil Soo Sung","doi":"10.17998/jlc.2022.09.17","DOIUrl":"https://doi.org/10.17998/jlc.2022.09.17","url":null,"abstract":"<p><p>Budd-Chiari syndrome (BCS) is defined by the obstruction of the hepatic venous outflow between the small hepatic veins and the junction of the inferior vena cava (IVC) with the right atrium. BCS with IVC obstruction occasionally progresses to hepatocellular carcinoma (HCC). Here, we report the case of a patient with HCC arising from a cirrhotic liver with BCS, in whom the hepatic portion of the IVC was obstructed, and who had a favorable outcome with a multidisciplinary approach and IVC balloon angioplasty.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"202-206"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/ca/jlc-2022-09-17.PMC10035740.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9734388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response to local therapy for advanced hepatocellular carcinoma with lung metastasis: a case report.","authors":"Daeun Kim,&nbsp;Seiyeon Park,&nbsp;Won Sohn,&nbsp;Hyun Pyo Hong,&nbsp;Byung Ik Kim","doi":"10.17998/jlc.2021.12.28","DOIUrl":"https://doi.org/10.17998/jlc.2021.12.28","url":null,"abstract":"<p><p>The concept of oligometastasis is widely accepted for various types of solid tumors; accordingly, better outcomes can be anticipated with aggressive local interventions. The treatment of advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis is systemic therapy. However, treatment responses to systemic therapy are poor. Recently, a small number of metastatic cancers (oligometastasis) have been controlled by local therapy rather than systemic therapy. Our study reports a case of a 66-year-old male patient with advanced HCC with lung metastasis, which was treated with local therapy. There were less than four metastases in the lungs, which were treated with wedge resection, radiofrequency, and radiation therapy. He repeatedly underwent local therapy for lung oligometastasis and locoregional therapy for intrahepatic HCC rather than systemic therapy; control by local therapy was possible as his liver function was preserved with Child-Turcotte-Pugh class A.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"51-56"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/36/jlc-2021-12-28.PMC10035712.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioembolization for hepatocellular carcinoma: what clinicians need to know.","authors":"Jin Woo Choi,&nbsp;Hyo-Cheol Kim","doi":"10.17998/jlc.2022.01.16","DOIUrl":"https://doi.org/10.17998/jlc.2022.01.16","url":null,"abstract":"<p><p>Transarterial radioembolization (TARE) with yttrium 90 (⁹⁰Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of ⁹⁰Y radioactive microspheres available, namely, glass and resin microspheres, with comparable clinical outcomes. In general, TARE outperforms transarterial chemoembolization regarding post-embolization syndrome, time to progression, tumor downsizing for liver transplantation, and hospitalization stay. Although TARE is commonly recommended for patients with unresectable large HCCs, it can be an alternative to or performed in combination with ablation, surgical resection, and systemic treatment. This review aimed to address ⁹⁰Y radioactive microspheres, patient selection, clinical outcomes, simulation tests, radioembolization procedures, follow-up imaging, and complications.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"4-13"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/42/jlc-2022-01-16.PMC10035707.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10096398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma.","authors":"Jihyun An,&nbsp;Hyo Jeong Kang,&nbsp;Eunsil Yu,&nbsp;Han Chu Lee,&nbsp;Ju Hyun Shim","doi":"10.17998/jlc.2022.03.06","DOIUrl":"https://doi.org/10.17998/jlc.2022.03.06","url":null,"abstract":"<p><strong>Background/aim: </strong>Immune checkpoint proteins regulating T-cell mediated anti-tumor immunity have been reported to affect clinical outcomes in multiple malignancies. This study aimed to investigate the prognostic effect of histological expression of immune checkpoint proteins in patients with resected hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>A total of 221 patients with HCC who underwent curative resection were included. Expression of programmed-cell death ligand-1 (PD-L1) in tumor cells (tPD-L1) and tumor infiltrating mononuclear cells (TIMCs) (iPD-L1), programmed-cell death-1 in TIMCs (iPD-1), and cytotoxic T lymphocyte antigen-4 in TIMCs (iCTLA-4) were measured immunohistochemically.</p><p><strong>Results: </strong>Histo-positivity for iCTLA-4, iPD-1, iPD-L1, and tPD-L1 was 32.1%, 42.5%, 35.3%, and 14.9%, respectively. Multivariate logistic analyses revealed that male sex and tumor >5 cm were variables related to iCTLA-4 positivity (odds ratio [OR], 0.46 and 1.94, respectively; <i>P</i><0.05). Poor differentiation was related to PD-L1 expression in both tumor cells and TIMCs (OR, 2.88 and 3.46, respectively; <i>P</i><0.05). Microvascular invasion was significantly associated only with iPD-L1 (OR, 2.24; <i>P</i><0.05). In time-dependent outcome analyses, expression of immune checkpoint proteins in TIMCs (i.e., iCTLA-4, iPD-1, and iPD-L1) was significantly related to longer overall survival and non-cancer-related survival (all <i>P</i><0.05), but not to time-to-recurrence or cancer-specific deaths. Concurrent activation of the PD-1:PD-L1 and CTLA-4 pathways predicted improved outcomes in terms of overall survival and non-cancer related survival (<i>P</i>=0.06 and <i>P</i>=0.03, respectively).</p><p><strong>Conclusions: </strong>Immune checkpoint proteins upregulated in TIMCs in HCC tissues have individual and additive effects in prolonging the survival of patients, specifically in terms of survival not related to cancer recurrence.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"40-50"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/0b/jlc-2022-03-06.PMC10035709.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma.","authors":"Jeong Won Jang,&nbsp;Ji Min Kim,&nbsp;Hye Seon Kim,&nbsp;Jin Seoub Kim,&nbsp;Ji Won Han,&nbsp;Soon Kyu Lee,&nbsp;Heechul Nam,&nbsp;Pil Soo Sung,&nbsp;Si Hyun Bae,&nbsp;Jong Young Choi,&nbsp;Seung Kew Yoon","doi":"10.17998/jlc.2022.02.25","DOIUrl":"https://doi.org/10.17998/jlc.2022.02.25","url":null,"abstract":"<p><strong>Background/aim: </strong>Hepatocellular carcinoma (HCC) is associated with poor prognosis, largely due to late detection. Highly accurate biomarkers are urgently needed to detect early-stage HCC. Our study aims to explore the diagnostic performance of serum exosomal microRNA (miR)-720 in HCC.</p><p><strong>Methods: </strong>Exosomal miRNA was measured via quantitative real-time PCR. A correlation analysis of exosomal miR-720 and tumor or clinico-demographic data of patients with HCC was performed. The receiver operating characteristic (ROC) curve was used to assess the diagnostic capacity of serum exosomal miR-720 for HCC, in comparison with α-fetoprotein (AFP) and prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II).</p><p><strong>Results: </strong>MiR-720 was chosen as a potential HCC marker via miR microarray based on significant differential expression between tumor and non-tumor samples. Serum exosomal miR-720 was significantly upregulated in patients with HCC (n=114) versus other liver diseases (control, n=30), with a higher area under the ROC curve (AUC, 0.931) than the other markers. Particularly, serum exosomal miR-720 showed superior performance in diagnosing small HCC (<5 cm; AUC, 0.930) compared with AFP (AUC, 0.802) or PIVKA-II (AUC, 0.718). Exosomal miR-720 levels showed marginal correlation with tumor size. The proportion of elevated miR-720 also increased with intrahepatic tumor stage progression. Unlike AFP or PIVKA-II showing a significant correlation with aminotransferase levels, the exosomal miR-720 level was not affected by aminotransferase levels.</p><p><strong>Conclusions: </strong>Serum exosomal miR-720 is an excellent biomarker for the diagnosis of HCC, with better performance than AFP or PIVKA-II. Its diagnostic utility is maintained even in small HCC and is unaffected by aminotransferase levels.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"30-39"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/a0/jlc-2022-02-25.PMC10035706.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clinical and pathological update on hepatocellular carcinoma.","authors":"Salvatore Lorenzo Renne,&nbsp;Luca Di Tommaso","doi":"10.17998/jlc.2022.03.18","DOIUrl":"https://doi.org/10.17998/jlc.2022.03.18","url":null,"abstract":"<p><p>It is estimated that more than 1 million individuals will be affected annually by hepatocellular carcinoma (HCC) by 2025. HCC can be broadly grouped into two major molecular subgroups, each of which is characterized by specific morphological and phenotypic features that mirror the genetic background. The use of these tissue biomarkers in the daily practice of pathologists promises to better allocate patients with HCC with adequate treatments. In turn, this will likely boost the attitude of clinicians toward obtaining a pre-treatment biopsy.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"14-22"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/29/jlc-2022-03-18.PMC10035711.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus?","authors":"Won Hyeok Choe","doi":"10.17998/jlc.2022.03.15","DOIUrl":"10.17998/jlc.2022.03.15","url":null,"abstract":"","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/a7/jlc-2022-03-15.PMC10035715.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma.","authors":"Ahlim Lee,&nbsp;Jaejun Lee,&nbsp;Hyun Yang,&nbsp;Soo-Yoon Sung,&nbsp;Chang Ho Jeon,&nbsp;Su Ho Kim,&nbsp;Moon Hyung Choi,&nbsp;Young Joon Lee,&nbsp;Ho Jong Chun,&nbsp;Si Hyun Bae","doi":"10.17998/jlc.2022.03.04","DOIUrl":"https://doi.org/10.17998/jlc.2022.03.04","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectable HCC with atezolizumab plus bevacizumab (AteBeva), therapeutic outcomes were unsatisfactory in more than half of the patients. Accordingly, many ongoing trials combine conventional modalities with new drugs such as immune checkpoint inhibitors for better treatment outcomes, and they are expected to benefit patients with limited responses to conventional treatment. Here, two patients with advanced stage HCC with preserved liver function and good performance status showed partial response after treatment with combination or sequential therapy of AteBeva, hepatic arterial infusion chemotherapy, radiation therapy, and transarterial chemoembolization. These findings indicate the efficacy of multidisciplinary treatment against advanced HCC. Additional studies are required to establish optimal treatment strategies.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 1","pages":"75-83"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/1e/jlc-2022-03-04.PMC10035713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}